Grok comparison of Fisetin and D+Q

#21

@argonaut , I just re-read your posts, and it seems like we’ve had similar thoughts and similar results from Grok and Gemini. I wonder what other supplements this might work for… so I’ve created this thread , starting with Urolithin A: DIY: inexpensive workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A at home

There may be easy ways to make DYI solutions that are similar to the liposomal formulations but much less expensive. See this query I did on urolithin A, (see second section below). Perhaps someone here with more experience in this are can dig deeper on this issue. (

from Gemini

The short answer is no, there are no authentic, high-efficiency “DIY” methods to produce true nano-micronized or nano-liposomal delivery systems at home using basic kitchen tools. The popular internet protocols—primarily using jewelry ultrasonic cleaning baths and soy lecithin—produce coarse macro-emulsions rather than true lipid-encapsulated nanoparticles.

However, there are highly practical, inexpensive chemical workarounds to significantly enhance the bioavailability of lipophilic compounds like Urolithin A (UA) at home without industrial equipment.

The Mechanical and Thermodynamic Bottlenecks of DIY Formulations

1. The Acoustic Energy Gap (Vesicle Size Failure)

To achieve the rapid cell-membrane fusion and lymphatic bypass associated with modern lipid delivery, liposomes must be Small Unilamellar Vesicles (SUVs) with a particle size between 20 nm and 200 nm.

  • The Reality of Ultrasonic Baths: Standard ultrasonic jewelry cleaners operate at low frequencies (35–40 kHz) and low power densities, distributed over a large water volume. Particle size distribution (PSD) analysis shows that bath sonication fails to disrupt large multilamellar vesicles (MLVs), resulting in particles consistently greater than 500–1,000 nm.
  • The Industrial Standard: True nano-encapsulation requires laboratory-grade probe sonicators or high-pressure microfluidizers that deliver concentrated acoustic cavitation directly into a small volume to violently shear lipid sheets into nanometer-scale spheres.

2. The Hydrophobic Loading Problem

Most online DIY liposome recipes are designed for hydrophilic (water-soluble) molecules like Vitamin C, which easily dissolve in the aqueous core of a lipid vesicle.

  • Urolithin A is highly lipophilic (hydrophobic). It has virtually zero aqueous solubility but dissolves in organic solvents (DMSO, DMF, absolute ethanol) and certain lipid phases.
  • If you simply mix raw UA powder, water, and lecithin into an ultrasonic bath, the UA crystals will remain un-encapsulated, suspended loosely in the water or clumped as an unstable macro-emulsion, providing zero kinetic or pharmacokinetic advantage.

Pragmatic, High-Bioavailability DIY Workarounds

To bypass the need for industrial nanotech, you can exploit the lipophilic nature of the compound by creating a Simplified Self-Emulsifying Drug Delivery System (SEDDS) or utilizing mechanical wet-milling.

1. The SEDDS Lipid Carrier Proxy (Highest Efficiency)

Instead of trying to force a liposome to form in water, dissolve the compound directly into a lipid matrix that the human digestive tract absorbs via the lymphatic system (bypassing first-pass liver metabolism). Preclinical data indicates that submicron oil-in-water emulsions drastically improve UA baseline bioavailability.

  • The Carrier: Medium-Chain Triglyceride (MCT) oil or high-oleic sunflower oil.
  • The Emulsifier/Surfactant: Liquid sunflower lecithin or food-grade Polysorbate 80 (Tween 80).
  • The Protocol:
    1. Warm a measured volume of MCT oil gently (approx. 50–60°C / 122–140°F). Do not overheat, as polyphenols can degrade.
    2. Add the raw Urolithin A powder alongside 10–20% liquid lecithin by volume.
    3. Agitate vigorously (using a high-shear laboratory stirrer or a high-speed milk frother) until the crystalline powder is fully solubilized or uniformly suspended in the lipid phase.
  • Why it works: When this lipid mixture hits gastric fluids and bile salts, it spontaneously forms crude micellar structures and micro-emulsions in the gut, mimicking commercial lipid-encapsulation mechanics.

2. Low-Cost Wet Milling (Mechanical Micronization)

If you prefer a solid or powder format, you can manually reduce particle size to increase surface area, which accelerates the dissolution rate in the intestine.

  • The Protocol: Place the raw compound into a ceramic mortar and pestle. Add a few drops of absolute ethanol (99% food-grade) and a small amount of powdered lecithin to create a thick paste. Grind aggressively for 15–20 minutes as the solvent evaporates.
  • Why it works: The shear force mechanically breaks down larger crystalline aggregates (micronization), while the amphiphilic lecithin coats the newly sheared micro-crystals, preventing re-agglomeration and improving wettability when it enters the gastrointestinal tract.

Knowledge Gaps & Uncertainties

While these lipid-carrier and wet-milling methods optimize the kinetic environment for absorption, the exact peak serum concentration (C_{max}) and Area Under the Curve (AUC) achieved via home preparation remain unquantified. Without analytical validation tools like Dynamic Light Scattering (DLS) or High-Performance Liquid Chromatography (HPLC), the exact percentage of compound successfully solubilized or micronized vs. what remains unabsorbed can only be estimated based on broad pharmaceutical principles.

#22

And, I asked it using the SEDDS approach with Fisetin:

The SEDDS Lipid Carrier Proxy method works exceptionally well with Fisetin. Due to its specific physicochemical properties, Fisetin is an even more critical candidate for lipid-based delivery strategies than Urolithin A.

Physicochemical Rationale for Fisetin

Fisetin (3,3′,4′,7-tetrahydroxyflavone) faces severe pharmacokinetic bottlenecks when ingested as a raw crystalline powder. Its delivery challenges stem from three main barriers:

ResearchGate

  • High Lipophilicity and Low Solubility: Fisetin has a partition coefficient (logP≈3.2) indicating high fat-solubility, but its aqueous solubility is extremely low at approximately 10.45 μg/mL. It cannot dissolve efficiently in the aqueous environment of the gastrointestinal tract.

PMC - NIH

  • Aggressive First-Pass Metabolism: Once in the intestine, Fisetin is rapidly metabolized by UDP-glucuronosyltransferases (UGTs) and sulfotransferases in both the gut wall and the liver. This converts free Fisetin into glucuronide and sulfate conjugates, significantly lowering its systemic potency.

PMC - NIH

  • Efflux Transporter Clearance: Fisetin is a known substrate for P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) efflux pumps, which actively pump the absorbed molecule out of enterocytes and back into the intestinal lumen.

PMC - NIH

Expected Bioavailability Multipliers

Peer-reviewed pharmacokinetic data evaluating self-emulsifying and lipid-nanoemulsion systems for Fisetin demonstrates massive absorption advantages over standard unformulated powder:

Formulation Type Bioavailability Increase (AUC) Cmax Increase Primary Mechanism Source
Liquid SEDDS / SNEDDS 6.86-fold ~5-fold Complete crystalline dissolution; surfactant-mediated mucosal permeation Gunjal et al., 2024
Self-Emulsified Micellar Hydrogel 26.9-fold 23.8-fold Maximum systemic exposure; protection against enterocyte degradation Joseph et al., 2022
Lipid Nanoemulsion (IP/Oral proxy) 24-fold Variable Direct lymphatic transport; evasion of hepatic clearance Ragelle et al., 2012

Why the Proxy Method is Highly Effective for Fisetin

When Fisetin is pre-dissolving into a mixture of Medium-Chain Triglyceride (MCT) oil and a phospholipid surfactant like sunflower lecithin, it alters the pharmacokinetic pathway in two ways:

1. P-gp Efflux Transporter Inhibition

Phospholipids and lipid degradation products naturally act as mild, non-toxic inhibitors of P-gp and BCRP efflux pumps in the brush border membrane. By co-administering Fisetin within a dense lipid-surfactant matrix, you temporarily saturate or inhibit these efflux pumps, allowing a higher percentage of free Fisetin to cross into the bloodstream.

2. Intestinal Lymphatic Targeting

The long-chain and medium-chain fatty acids in the carrier stimulate the secretion of chylomicroons by the enterocytes. Highly lipophilic molecules (logP>3) dissolve into these chylomicrons and enter the lymphatic system via the lacteals. Because the lymphatic system empties directly into the systemic circulation via the thoracic duct, a portion of the Fisetin completely bypasses the portal vein and avoids initial first-pass hepatic glucuronidation.

Practical Formulating Caveat for DIY Fisetin SEDDS

Fisetin possesses a highly stable crystalline lattice with strong intermolecular hydrogen bonding, giving it a high melting point (~330°C). This makes it significantly more stubborn to dissolve in pure oils than Urolithin A.

To achieve complete solubilization in a DIY setting, the oil matrix must be held at 55–60°C (131–140°F) during mixing, and the ratio of surfactant (lecithin) must be increased to roughly 20–25% of the total lipid volume to serve as a co-solvent. If the mixture appears cloudy or exhibits sediment upon cooling, the Fisetin has recrystallized, which will reduce the expected bioavailability multiplier back toward baseline.